Tirbanibulin

Brand names: Klisyri · Active ingredient: Tirbanibulin

In short: KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp.

Forms & strengthsOintment: 1% white to off-white ointment supplied in a unit-dose packet (2.5 mg tirbanibulin in 250 mg or 3.5 mg tirbanibulin in 350 mg).
LabelAlmirall, LLC
Label updatedSep 07, 2026

What is Tirbanibulin used for?

KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp.

Tirbanibulin dosage

For topical use only; not for oral or ophthalmic use.

Apply KLISYRI evenly to cover up to 100 cm2 treatment field on the face or balding scalp once daily for 5 consecutive days using 1 unit-dose packet per application.

Wash hands immediately with soap and water after application.

Avoid washing and touching the treated area for approximately 8 hours after application of KLISYRI. Following this time, the area may be washed with a mild soap.

Avoid transfer of KLISYRI to the periocular area .

Avoid application near and around the mouth and lips.

How to take Tirbanibulin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Ophthalmic Adverse Reactions

Advise patients that KLISYRI is not for ophthalmic use. Advise patients to avoid application around the eyes, and transfer of the drug into the eyes and to the periocular area. If accidental exposure occurs, advise patients to flush eyes with water and seek medical care .

Local Skin Reactions

Inform patients that treatment with KLISYRI may lead to local skin reactions .

Important Administration Instructions

Advise patients that KLISYRI is for topical use only. Advise patients to avoid application near and around the eyes, mouth and lips.

Instruct patients to:

Wash hands well after applying KLISYRI to avoid transfer of the drug into the eyes and to the periocular area after application.

Avoid washing and touching the treated area for 8 hours after treatment. Following this time, patients may wash the area with a mild soap and water .

Avoid inadvertent transfer of KLISYRI to other areas, or to another person.

Manufactured for: Almirall, LLC

Malvern, PA. 19355, USA

Warnings & precautions

Do not take this medicine if: None.

KLISYRI may cause eye irritation.

Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration) in the treated area can occur after topical application of KLISYRI . Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.

Tirbanibulin side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Two double-blind, vehicle-controlled clinical trials were conducted in 702 adult subjects with actinic keratosis on the face or scalp. Subjects were randomized 1:1 to KLISYRI or vehicle. Subjects enrolled in the trials had 4 to 8 clinically typical, visible, and discrete AK lesions in a contiguous area of 25 cm2 on the face or scalp. Subjects’ average age was 70 years (range 45 to 96 years) and they were predominantly White (99%), male (87%), with Fitzpatrick skin types I or II (72%) and actinic keratosis on the face (68%) or scalp (32%). Treatment groups were comparable across all demographics and baseline characteristics, including AK lesion count and distribution on the face or scalp.

In the controlled trials, local skin reactions (LSRs) were collected independent of adverse events. Local skin reactions including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosions/ulcerations were assessed by the investigators using a grading scale of 0 = absent, 1 = mild (slightly, barely perceptible), 2 = moderate (distinct presence), and 3 = severe (marked, intense). …

About this medicine

KLISYRI (tirbanibulin) ointment is a microtubule inhibitor for topical use. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. The molecular weight is 431.4 and the molecular formula is C26H29N3O3. Tirbanibulin’s structural formula is:

Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol.

How it works: Tirbanibulin is a microtubule inhibitor. The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown. The pharmacodynamics of tirbanibulin in the treatment of actinic keratosis is unknown.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 589c8de8-b773-4d47-b60c-48471806cccc. Read the full official label on DailyMed.